相关实验视频

Updated: Jun 28, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

癌症治疗中的circRNAs耐受性

Miao He¹, Yunyan Pan², Chongge You²

¹The Second Hospital of Lanzhou University, Laboratory Medicine Center, Lanzhou 730030, PR China; The Second Clinical Medical School, Lanzhou University, Lanzhou 730030, PR China.

Clinica chimica acta; international journal of clinical chemistry

|April 22, 2024

概括

血清中的循环RNAs (circRNAs) 显示为预测癌症治疗耐药性和结果的非侵入性生物标志物具有前途. 进一步的研究旨在将circRNA分析纳入个人化瘤学的临床实践.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

循环RNAs (circRNAs) 正在成为癌症的关键调节者.
血清环RNA因其稳定性和丰富性而具有作为非侵入性生物标志物的潜力.
了解circRNA的作用对于推进癌症诊断和治疗至关重要.

研究的目的:

审查癌症中circRNAs的生物发生,功能和临床相关性.
突出血清circRNAs作为预测瘤治疗耐药性的生物标志物.
讨论临床瘤学中circRNA研究的挑战和未来前景.

主要方法:

关于癌症中circRNAs的现有研究和临床试验的综合文献综述.
分析circRNA在瘤发生,瘤进展和治疗反应中的作用.
对血清circRNAs进行预后意义和耐药性预测的评估.

主要成果:

循环RNA在瘤发生过程中起着复杂的作用,并影响患者对化疗,放射治疗,向治疗和免疫治疗的反应.
血清cirRNAs在预测治疗结果和抵抗机制方面具有预后意义.
循环RNA分析有能力为个性化癌症治疗策略提供信息.

结论:

血清circRNAs是早期癌症诊断和治疗耐受性预测的有希望的非侵入性生物标志物.
需要用于circRNA提取和定量化的标准化协议.
将circRNA分析整合到临床工作流程中,可以推进精确瘤学和新型治疗方法.

关键词:

癌症癌症癌症癌症液体活检液体活检治疗耐受性治疗耐受性环RNA 环RNA 是一个环RNA.

更多相关视频

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...